South America Metered Dose Inhalers Market

ID: MRFR/HC/48605-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
South America Metered Dose Inhalers Market Research Report By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Regional (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035
South America Metered Dose Inhalers Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.13%
2024 Market Size$ 1,710 Million
2025 Market Size$ 1,780.62 Million
2035 Market Size$ 2,670 Million
Key Players
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
Mylan
Opportunities
  • Rising Healthcare Expenditure
  • Increasing Air Pollution Levels
  • Supportive Regulatory Frameworks
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Product (USD Million)
      1. 4.1.1 Press Metered Dose Inhalers
      2. 4.1.2 Breath Actuated Metered Dose Inhalers
    2. 4.2 Industrial Automation & Equipment, BY Propellant Type (USD Million)
      1. 4.2.1 HFA 134a
      2. 4.2.2 HFA 227ea
      3. 4.2.3 HFA-152a
    3. 4.3 Industrial Automation & Equipment, BY Technology (USD Million)
      1. 4.3.1 Pulmonary Platform Technologies
      2. 4.3.2 Nasal Platform Technologies
    4. 4.4 Industrial Automation & Equipment, BY Indication (USD Million)
      1. 4.4.1 Asthma
      2. 4.4.2 COPD
      3. 4.4.3 Others
    5. 4.5 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
      1. 4.5.1 Hospital Pharmacies
      2. 4.5.2 Retail Pharmacies
      3. 4.5.3 Online Pharmacies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AstraZeneca (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 GlaxoSmithKline (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Mylan (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY PRODUCT
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY PROPELLANT TYPE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PRODUCT, 2024 (% SHARE)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PRODUCT, 2024 TO 2035 (USD Million)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PROPELLANT TYPE, 2024 (% SHARE)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PROPELLANT TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 (% SHARE)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 (% SHARE)
    20. 6.20 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 TO 2035 (USD Million)
    21. 6.21 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY PROPELLANT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
      4. 7.2.4 BY INDICATION, 2025-2035 (USD Million)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Metered Dose Inhalers Market Segmentation

South America Metered Dose Inhalers Market By Product (USD Million, 2025-2035)

  • Press Metered Dose Inhalers
  • Breath Actuated Metered Dose Inhalers

South America Metered Dose Inhalers Market By Propellant Type (USD Million, 2025-2035)

  • HFA 134a
  • HFA 227ea
  • HFA-152a

South America Metered Dose Inhalers Market By Technology (USD Million, 2025-2035)

  • Pulmonary Platform Technologies
  • Nasal Platform Technologies

South America Metered Dose Inhalers Market By Indication (USD Million, 2025-2035)

  • Asthma
  • COPD
  • Others

South America Metered Dose Inhalers Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.